Cadila Healthcare is currently trading at Rs 332.35, up by 5.55 points or 1.70% from its previous closing of Rs 326.80 on the BSE.
The scrip opened at Rs. 329.45 and has touched a high and low of Rs. 333.80 and Rs. 321.70 respectively. So far 103921 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 285.73 on 09-Feb-2015.
Last one week high and low of the scrip stood at Rs. 333.80 and Rs. 305.40 respectively. The current market cap of the company is Rs. 34024.09 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 14.35% and 10.86% respectively.
Cadila Healthcare has reported 29.98% rise in its net profit at Rs 469.50 crore for the quarter ended December 31, 2015 as compared to Rs 361.20 crore for the same quarter in the previous year. The company’s total income has increased by 20.36% to Rs 1775.50 crore for the quarter under review from Rs 1475.10 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 38.21% rise in its net profit after taxes, minority interest and share of profit of associates of Rs 389.60 crore for the quarter ended December 31, 2015 as compared to Rs 281.90 crore for the same quarter in the previous year. Total income of the company has increased by 10.79% at Rs 2453.90 crore for quarter under review as compared to Rs 2214.90 crore for the quarter ended December 31, 2014.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: